EP Patent

EP2684564A1 — Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation

Assigned to Sanofi SA · Expires 2014-01-15 · 12y expired

What this patent protects

Use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or for use in the prevention of atrial fibrillation/flutter in patients with a history of or a current non permament at…

USPTO Abstract

Use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or for use in the prevention of atrial fibrillation/flutter in patients with a history of or a current non permament atrial fibrillation/flutter.

Drugs covered by this patent

Patent Metadata

Patent number
EP2684564A1
Jurisdiction
EP
Classification
Expires
2014-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.